Metabolomics

A CU Anschutz research team, experts in athletes’ baseline metabolic profiles and how these physiologies change during competition, are helping guide some of the world’s elite athletes to their best performances, including the recent Tour de France winner. Their understanding of the metabolic underpinnings of top athletes has implications for improved treatments of disease, including […]

Metabolon, has announced the close on $72 million in combined debt and equity financing. This round of financing included Perceptive Advisors as a new participant. EW Healthcare Partners and other existing investors also participated in the financing. “We are thrilled by this strong show of support from Perceptive Advisors and our current investors,” said Rohan […]

Lu Rahman speaks to key members of Metabolon on the company’s pioneering work in metabolomics including its innovative collaborations with DNAGenotek and the Institute for Systems Biology. “Metabolon has built an unrivalled global biochemical profiling platform capable of providing metabolite data of unsurpassed quality and coverage,” says Brian Keppler, PhD, Director, Discovery and Translational Sciences at […]

Collaborative Research Leads To New Understanding Of Biomarkers By Dr Max Ryadnov and Professor Jason Crain A new collaborative research paper sheds light on the way antibodies distinguish between different but closely related ‘biomarkers’ – in this case protein fragments which reveal information about the condition of the human body. This new understanding could enable […]

Thermo Fisher Scientific will provide online programming and virtual exhibits to introduce scientists to a number of new products that build on its leading Orbitrap platform and expand research applications. The company said it will showcase its newest instruments, software and workflow solutions during a company-hosted virtual event, vLC-MS.com, on May 26 -28, 2020, and at […]

6 July 2020 Image: Science in HD Eremid Research Services is the new name for the commercial arm of research organisation, DHMRI. Eremid continues to specialise in the provision of genomics, metabolomics, NMR and vivarium research services, offering expertise in areas including human health, food & nutrition, and AgBiotech. The company offers a ‘multi-omics’ approach, working with clients across the globe […]

Share Share Tweet Email Could marine alga be a remedy against infections and skin cancer? Could marine alga be a remedy against infections and skin cancer? 6 July 2020 Image: Shane Stagner Marine organisms and their microbial symbionts are invaluable sources of new medicines for human diseases. Natural products from the sea have four times […]

25 June 2020 Metabolon and DNA Genotek have teamed up to create OMNImet-GUT, said to be the first device for in-home collection and ambient-temperature storage and shipping of faecal samples for metabolomics, to the research market. “For years, our customers from across biopharma, academia and population health have been asking for a validated, ambient-temperature solution […]

Harnessing the modified proteome for increased diagnostic power By Dr David Bramwell, Dr Steven Laval and Dr Jane McLeod Relevant biomarkers are vitally important in personalised medicine, guiding patient matching to specific therapies for earlier, easier and more effective disease identification and treatment. Here we trace the expectations of ’omicsbased healthcare interventions, from the increased […]

The Mass Spectrometry Innovations Simplifying Drug Discovery Workflows Helen Stewart-Miller and Dr Richard Massey Mass spectrometry (MS) has long been a valuable tool for drug discovery, and steady advances in its capabilities and performance have generated powerful insights for the pharmaceutical industry. The latest mass spectrometry innovations are now helping biotherapeutics developers overcome challenges around […]

Disruptive Approaches To Accelerate Drug Discovery and Development (Part 1) By Ibis Sanchez- Serrano, Dr Tom Pfeifer and Dr Rathnam Chaguturu This article is part 1 of 2, and covers tools, technologies and the core model of disruptive approaches to accelerate drug discovery and development. Tesla intends to implement and practise an ‘open source’ philosophy […]

Immuno-Oncology’s Biomarker Dilemma: How to add value in an uncertain development landscape By Dr Rachel Laing and Olivier Lesueur Given their ability to promote long-term survival in a percentage of cancer patients, PD-1/PD-L1 checkpoint inhibitors have fast become foundational cancer therapies. But knowing which patients may respond to these drugs is challenging, in large part […]

Translational Chemical Biology: Gap assessment for advancing drug discovery, development and precision medicine By Dr Mukund Chorghade, Dr Michael Liebman, Dr Gerald Lushington, Dr Stephen Naylor and Dr Rathnam Chaguturu As yesterday’s lead molecule enters today’s clinical trial, the standard operating script seems to call for product developers and clinicians to push away the originating […]

I Robot. I, The Future – Robotics Within and Beyond The Lab Richard Holland The Pistoia Alliance (whose membership includes most of the world’s major pharmaceutical companies, technology vendors and publishers active in the life science R&D sector), is keenly interested in discovering the ways in which innovation through pre-competitive collaboration can be used to […]

Breath Based Biomarker Detection & Breath Biopsy – Informing drug development and future treatment regimes By Billy Boyle and Dr Mike Murphy The recent approval of the first liquid biopsy test for the diagnosis of non-small cell lung cancer (NSCLC) demonstrates how biomarker-based detection tools are becoming important components of precision medicine-based drug treatment regimes. […]

By Dr A Roy, Prof B Patwardhan and Dr R Chaguturu Modern drug discovery approaches take too long, are too expensive, have too many clinical failures and uncertain outcomes. There are many reasons for this unsustainable business model, but primarily, the approaches are not comprehensively holistic. Secondly, none of the pharmaceutical companies openly share the […]